01997nas a2200193   4500000000100000008004100001260001600042653001500058653001700073653002100090653001800111653001800129100003100147245011300178856007600291300001100367520140300378020002201781       2013                            d  bWHOaGeneva10aPrevention10aEpidemiology10aEndemic Diseases10aElephantiasis10aComplications1 aWorld Health Organization 00aLymphatic filariasis: managing morbidity and preventing disability: an aide-mémoire for national programme.  uhttp://apps.who.int/iris/bitstream/10665/85347/1/9789241505291_eng.pdf   a69 p. 3 a<p>The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was launched by the World Health Organization (WHO) in 2000.</p>

<p>The Programme has two main components:</p>

<p>• interrupting transmission of lymphatic fi lariasis through mass drug administration, and</p>

<p>• managing morbidity and preventing disability.</p>

<p>Good progress was made with mass drug administration between 2000 and 2010, with over 3.9 billion doses of medicine delivered to a cumulative targeted population of 952 million people (<em>1</em>). Interventions to prevent and manage lymphatic filariasis-related disabilities in endemic communities were, however, limited.</p>

<p>In 2010, WHO published the GPELF progress report and strategic plan for the first 10 years of the Programme, with an outline of the approach and milestones for the second 10 years (<em>2</em>). One of the milestones is to disseminate revised.</p>

<p>This document provides guidance on planning, implementing and monitoring activities at national level. It provides the best available information on managing morbidity and preventing disability after acute dermatolymphangioadenitis (ADLA; acute attacks), lymphoedema or elephantiasis, and hydrocoele. It also provides general operational and managerial guidance for reducing the number of cases of lymphatic filariasis and providing care for those affected.</p>
  a978 92 4 150529 1